Carlos Henrique Menke

Sexual function and chemotherapy in postmenopausal women with breast cancer

BackgroundThis cross-sectional, nested cohort study assessed Female Sexual Function Index (FSFI) scores in postmenopausal women with breast cancer receiving primary chemotherapy.MethodsThe FSFI questionnaire was administered to 24 postmenopausal women one month after diagnosis of breast cancer (post-diagnosis group) and one month after completion of the first cycle of primary anthracyclin-based chemotherapy (post-chemotherapy group). Scores were compared to those of 24 healthy postmenopausal women seeking routine gynecological care (control group). All patients were sexually active at the time of enrollment. Mean age was 57.29 ± 11.82 years in the breast cancer group and 52.58 ± 7.19 years in the control group.ResultsScores in all domains of the FSFI instrument were significantly lower in the post-diagnosis group than in controls (−41.3%, p < 0.001). A further major reduction in FSFI scores was evident on completion of one cycle of primary chemotherapy (down 46.7% from post-diagnosis scores, p < 0.003), again in all domains. Six patients (25%) ceased all sexual relations, in a significant change from baseline (p < 0.001). After one chemotherapy cycle, a further five patients ceased sexual activity, for a total of 11 (45.8%) participants – a borderline significant difference (p = 0.063).ConclusionThe present study shows that female sexual function as assessed by the FSFI declines significantly at two distinct points in time: upon diagnosis of breast cancer and after administration of systemic chemotherapy.

Tumor Size as a Surrogate End Point for the Detection of Early Breast Cancer: A 30-Year (1972–2002), Single-Center Experience in Southern Brazil

Abstract:  The 30‐year experience in improving detection of breast cancer in the Breast Unit of the Hospital de Clínicas, Federal University of Rio Grande do Sul, Brazil (1972–2002) is reported. We retrospectively analyzed the behavior of surrogate parameters of early breast cancer detection, such as the mean tumor diameter at diagnosis, clinical staging, as well as the percentage of breast conservative surgery along this period of three decades. From 2,103 identified women, 1,607 women met our criteria for study entry and had follow‐up information, constituting our study cohort. Statistical tests were two‐sided and considered significant at p < 0.05. There was a decrease of about 0.8 cm in the median tumor diameter over this 30‐year period. The incidence of early‐stage tumors increased progressively over time, and the percentage of patients presenting with stage I breast cancer doubled in 30 years. The Halsted procedure that represented 11.5% of surgeries in the 1970s is a very rare procedure nowadays (<1% of cases). Modified radical mastectomy was the procedure applied in about 50% of women with invasive breast cancer during these 30 years of observation. Notably, breast conservative surgery increased from 17.3% in the 1970s to 43.2% in the 2000s, while the decrease in tumor size and clinical staging was accompanied by an increased number of breast conservative surgical procedures. In geographic areas where coordinated preventive efforts are not thoroughly available, analysis of subsets of the patient population using tumor size as a surrogate represents an indirect way to observe long‐term effects of prevention. The present study shows that tumor size is a surrogate for populations from developing countries too and gives scientific support for the design of continuous comprehensive programs of breast cancer prevention in this setting.

Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group.

Breast cancer is the main cause of cancer-related death among women, with a 0.5% increase in incidence per year. Natural killer cells (NK) are part of the innate immune system recognizing class I HLA molecules on target cells through their membrane receptors, called killer cell immunoglobulin-like receptors (KIR). The aim of our study was to evaluate the association between the KIR genes and HLA alleles in patients with breast cancer and healthy controls. Two hundred thirty patients with breast cancer and 272 healthy controls were typed for HLA class I and KIR genes by PCR-SSO. When both groups were compared, the presence of inhibitory KIR2DL2 receptors was significantly higher in breast cancer patients than in healthy controls. No significant differences were found for HLA-C2 and HLA-Bw4. However, a higher frequency of HLA-C1 in breast cancer patients was observed. These findings suggest a potential role for the KIR gene system in breast cancer. Further studies to confirm this observation are warranted.

Intraoperative injection of technetium-99m-dextran 500 for the identification of sentinel lymph node in breast cancer

PURPOSE to determine the efficacy of intraoperative injection of Dextran-500-99m-technetium (Tc) for the identification of the sentinel lymph node (SLN) in breast cancer and analyze time to label the SLN in the axillary region. METHODS a prospective study between April 2008 and June 2009, which included 74 sentinel lymph node biopsies (SLNB) in patients with breast cancer in stages T1N0 and T2N0. After induction of anesthesia, 0.5 to 1.5 mCi of Dextran-500-99m-Tc filtered 0.22 µm in a volume of 5 mL was injected intraoperative using the subareolar technique for SLNB. After labeling with the radioisotope, 2 mL of patent blue was injected. The time elapsed between injection and the axillary hot spot, the in vivo and ex vivo counts of the hottest nodes, the background count, and the number of SLN identified were documented. Data were analyzed using descriptive statistics with SPSS program, version 18. RESULTS we identified the SLN in 100% of cases. The rate of SLN identification with the probe was 98% (73/74 cases). In one case (1.35%) the SLN was labeled only with the blue dye. The mean dose of radioisotope injected was 0.97 ± 0.22 mCi. The average time to label the SLN was 10.7 minutes (± 5.7 min). We identified on average of 1.66 SLN labeled with the radioisotope. CONCLUSION the procedure for SLN identification with an intraoperative injection of the radioisotope is oncologically safe and comfortable for the patient, providing agility to the surgical team.

Analysis of the R72P polymorphism of the TP53 gene in patients with invasive ductal breast carcinoma.

Breast cancer is the most common neoplasia as well as the main cause of cancer-related death among women, experiencing a 0.5% increase in incidence per year. The disease results from a series of mutations in the DNA development and repair genes. Approximately 50% of human carcinomas present mutations in the TP53 gene. Polymorphisms of TP53 include codon 72 containing either arginine (CGC) or proline (CCC). Such polymorphisms may be involved in the susceptibility and predisposition to cancer, presenting a widely variable ethnic and geographic distribution. The arginine homozygous genotype seems to be a significant risk factor for breast cancer. The purpose of this study was to determine the frequency of the R72P polymorphism of the TP53 gene in patients with invasive ductal breast cancer from southern Brazil, where this type of cancer has a high incidence, as well as its association with breast carcinoma and clinicopathological characteristics. Seventy-six patients suffering from invasive ductal breast cancer and 80 controls were analyzed, and samples were evaluated by PCR followed by restriction enzyme digestion. No statistical differences in terms of the genotype frequency (P=0.707) or the arginine and proline allele frequencies (P=0.469) involving codon 72 were found in patients compared to controls. Thus, statistical analysis did not suggest any association between the R72P polymorphism of the TP53 gene and invasive ductal carcinoma in the population studied. Additionally, no significant association with the clinicopathological characteristics presented by the breast carcinoma patients was found.

Comparação da linfocintilografia com dextrano 500 com a do fitato na pesquisa do linfonodo sentinela no câncer de mama

OBJETIVO: comparar a acuracia de dois radiocoloides na marcacao do linfonodo sentinela (LNS) por imagem. METODOS: as pacientes foram incluidas no periodo de maio de 2002 a abril de 2004. Neste estudo duplo-cego, a paciente foi submetida duas vezes ao mesmo exame, mas com farmacos diferentes, sendo que os farmacos, tecnecio-99m-dextrano 500 (dextrano) e tecnecio-99m-fitato (fitato), foram injetados, na mama, em quatro pontos na area peritumoral e no subcutâneo superficialmente ao tumor, com volume de 2 ml, contendo de 1,0 a 1,5 mCi, em aliquotas de 0,4 ml. Para a obtencao das imagens, duas horas apos a injecao do radiofarmaco, usamos gama-câmera com colimador de alta resolucao. A drenagem linfatica axilar foi identificada em imagens radiograficas estaticas, anterior e lateral. A estatistica para pares discordantes foi realizada pelo teste de MacNemar e pelo teste Z para proporcoes. RESULTADOS: na analise das 40 pacientes, obtiveram-se 15 pares com imagens positivas iguais, 4 pares com imagens negativas e 21 pares com imagens distintas, seja porque uma era negativa, seja porque o numero de LNS marcados era diferente. A analise do desempenho quanto ao sucesso e insucesso mostrou 35 e 27 imagens positivas e 5 e 13 imagens negativas, respectivamente para o dextrano e o fitato, sendo que das negativas 4 eram comuns. O estudo estatistico pelo teste de MacNemar mostrou p=0,026, com odds ratio (OR) = 0,11 e IC 95% 0,01<OR<0,85. A taxa de sucesso foi 67,5% para o fitato e 87,5% para o dextrano 500 e a avaliacao da acuracia pelos percentuais tambem foi significante, com p=0,032. Pela ANOVA o numero de LNS apontados, foi altamente significante, com p=0,008. CONCLUSAO: este estudo demonstra que a linfocintilografia com dextrano 500 indica linfonodos com mais frequencia que o fitato, quando usados com a mesma metodologia, na obtencao da imagem do LNS de tumores da mama.